Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes. uri icon

authors

  • Kutz, Alexander
  • Dae Hyun Kim, MD, MPH, ScD
  • Wexler, Deborah J
  • Liu, Jun
  • Schneeweiss, Sebastian
  • Glynn, Robert J
  • Patorno, Elisabetta

publication date

  • January 1, 2023